New UK Drug Applications At ‘Sustained Levels’ Post-Brexit
MHRA Vaunts ‘Exciting’ New Operating Model
The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.
